To detect hFasL/Apo1 by direct ELISA (using 100 μ,L/well antibody solution) this antibody can be used at a concentration of 0.15-0.30 μ,g/mL. Used in conjunction with compatible secondary reagents, allows the detection of at least 0.2 ng/well of recombinant hFasL/Apo1.
Sandwich: To detect hFasL/Apo1L by sandwich ELISA (using 100 μ,L/well antibody solution) a concentration of 0.25 - 1.0 μ,g/mL of this antibody is required. This biotinylated polyclonal antibody, in conjunction with our Polyclonal Anti-Human FasL/Apo1L (XP-5130) as a capture antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hFasL/Apo1L.
Western Blot:
To detect hFasL/Apo1 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μ,g/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant hFasL/Apo1 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Restrictions
For Research Use only
Format
Lyophilized
Storage
-20 °C
Storage Comment
Fas Ligand antibody is stable for at least 2 years from date of receipt at -20°C. The reconstituted antibody is stable for at least two weeks at 2-8°C. Frozen aliquots are stable for at least 6 months when stored at -20°C. Avoid repeated freeze-thaw cycles.
Target
FASL
(Fas Ligand (TNF Superfamily, Member 6) (FASL))
Fas Ligand is an important member of the tumour necrosis factor (TNF) superfamily involved in membrane mediated apoptosis. Ligation of Fas by Fas Ligand or an anti Fas cross linking antibody, triggers activation of the caspase cascade. Functional impairment of the Fas / Fas Ligand system is associated with the development and progression of malignancies. Fas gene mutations have been suggested to have a role in testicular germ cell tumors. Tumor cells frequently exhibit de novo expression of Fas Ligand, which plays a significant role in local tissue destruction, metastatic spread, and immune escape of the tumor cells. The apoptosis of lymphocytes, which occurs in autoimmune diseases, is usually induced by the Fas/Fas Ligand system.